Novartis drug for hives misses endpoint

Tuesday 21 December 2021
Country

Switzerland

A monoclonal antibody developed by Novartis to treat chronic spontaneous urticaria, also known as chronic hives, did not show superiority to the marketed drug omalizumab in two Phase 3 trials. Announcing the trial results on 20 December, Novartis said that ligelizumab demonstrated superiority against placebo but not against omalizumab, known commercially as Xolair. Xolair, developed by Roche, has been approved for six indications in the US, including chronic idiopathic urticaria.